Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

AstraZeneca AZ

AZ gets first OK for PD-L1 inhibitor durvalumab

US regulators also approve Roche’s Ventana

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

- PMLiVE

Novartis’ Rydapt approval ends long AML therapy drought

Targeted blood cancer drug wins US licence from the FDA

- PMLiVE

Are celebrities bad for your health… communications?

The premium on the famous means their social media interactions can be valuable for comms and disease awareness

- PMLiVE

Sandoz UK promotes Tim de Gavre to country head

He succeeds Stephan Eder who becomes country head for Sandoz Germany

- PMLiVE

Frequency Therapeutics appoints Steven Dworetzky

The US firm has also promoted Raj Manchanda to chief development officer

Online therapy for dementia carers to be studied

UK researchers will assess computerised Cognitive Behaviour Therapy

- PMLiVE

Healthcare transformation and innovation

The healthcare and technology revolution

How to get your sales force to use digital tools

You have the perfect digital strategy. You provide the most advanced digital sales tools. You power it with amazing content. And then discover that customer-facing staff aren’t using it. Wait....

Anthill Agency

Bayer symbol

FDA OK for Stivarga ends decade-long drought in liver cancer

Bayer's medicine wins US approval to treat hepatocellular carcinoma

- PMLiVE

Cancer Drugs Fund “may have harmed patients”

Researchers claim most CDF drugs failed to show benefits to patients

- PMLiVE

The Communiqué Awards at 20: Mark Flannagan

Beating Bowel Cancer's former chief executive on changes in healthcare comms

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links